The data in this report was provided using a combination of benchmarking data around drug pipeline prioritization, partnerships, and acquisitions, and drug approvals. At the end of the report, we include a list of large impact drug catalysts through Q2 2023.

You can also download the PDF by clicking the button below

Related Resources

APR 01, 2023
White paper

2022 Deal-Making Roundup

An overview of alliance, M&A, and financing deal activity across the worldwide biopharma, medical device, and in vitro diagnostics industries during 2022

JUL 01, 2023

Q3 2023 Pharma Outlook Report

In this report, we cover catalysts from 29 drugs, devices, diagnostics, and deals expected to occur in Q3 2023.